Mundipharma EDO initiates Phase I/II oncology trial of tinostamustine in US

Switzerland-based Mundipharma EDO has initiated a Phase I/II clinical trial of tinostamustine (EDO-S101) to treat patients with advanced solid tumours in the US.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news